Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts rate LNTH a "Moderate Buy": 11 firms cover the stock (8 buy, 3 hold) with an average 12‑month price target of about $88.86.
• Quarterly results beat expectations: Lantheus reported $1.67 EPS vs. $1.17 expected and $406.8M revenue vs. $367.0M expected, and set FY2026 guidance of $5.00–$5.25 EPS (consensus for the current year is 4.29).
• Significant institutional buying: Large new and increased positions from M&T Bank (~$371M) and Farallon (~$361M) helped push institutional ownership to about 99.06% of shares outstanding.

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) have earned an average rating of "Moderate Buy" from the eleven ratings firms that are presently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $88.8571.

Several research firms have weighed in on LNTH. Citizens Jmp raised their price objective on shares of Lantheus from $73.00 to $78.00 and gave the company a "market outperform" rating in a research report on Tuesday, February 24th. B. Riley Financial restated a "buy" rating on shares of Lantheus in a research report on Friday. Jefferies Financial Group reiterated a "buy" rating and issued a $110.00 price objective on shares of Lantheus in a research report on Tuesday, March 17th. Mizuho increased their price objective on Lantheus from $85.00 to $95.00 and gave the company an "outperform" rating in a research report on Monday, April 13th. Finally, Citigroup reiterated an "outperform" rating on shares of Lantheus in a research report on Tuesday, February 24th.

Lantheus Stock Performance

Shares of LNTH opened at $85.50 on Monday. The stock has a fifty day moving average price of $78.85 and a two-hundred day moving average price of $68.21. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.51 and a current ratio of 2.70. Lantheus has a 52-week low of $47.25 and a 52-week high of $108.91. The company has a market cap of $5.57 billion, a price-to-earnings ratio of 25.37 and a beta of -0.08.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.50. The firm had revenue of $406.79 million during the quarter, compared to analysts' expectations of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company's quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.59 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts predict that Lantheus will post 4.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in LNTH. M&T Bank Corp acquired a new position in Lantheus during the 4th quarter valued at about $370,950,000. Farallon Capital Management LLC lifted its position in Lantheus by 56.1% during the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider's stock valued at $361,199,000 after purchasing an additional 1,950,252 shares during the period. Norges Bank acquired a new position in Lantheus during the 4th quarter valued at about $76,197,000. Polaris Capital Management LLC acquired a new position in Lantheus during the 3rd quarter valued at about $32,687,000. Finally, Freestone Grove Partners LP lifted its position in Lantheus by 4,114.8% during the 4th quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider's stock valued at $40,497,000 after purchasing an additional 594,088 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.